R Squared’s KalVista Pharmaceuticals KALV Stock Holding History

R Squared’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-110	Closed	-$932	–	907
2024 Q4	$932	Buy	+110	New	+$1.14K	﹤0.01%	1518

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

R Squared's KALV Position: Q1 2025 in Review

R Squared sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 110 shares — an estimated $932 sold.

R Squared first reported a position in KALV in Q4 2024 and held it in 1 quarter. The position peaked at $932 in Q4 2024. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

R Squared reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 110 KalVista Pharmaceuticals shares in Q1 2025, an estimated $932.
R Squared first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's KalVista Pharmaceuticals position peaked at $932 in Q4 2024.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.